Breaking News

Phenex, Janssen in Autoimmune Pact

December 17, 2012

To discover compounds targeting hormone receptor

Phenex Pharmaceuticals AG has entered into an agreement with Janssen Biotech, Inc. to jointly discover compounds that target the nuclear hormone receptor RORγT with the potential to treat chronic autoimmune and inflammatory disorders such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
 
Phenex will receive an upfront payment and development milestones totaling as much as $135 million. Phenex is also eligible to receive royalties and milestones for any product sales resulting from the collaboration. Janssen will have sole responsibility for the continued development and worldwide commercialization.
 
“This collaboration represents a landmark deal for Phenex,” said Dr. Claus Kremoser, chief executive officer of Phenex. “It combines Phenex’s nuclear receptor expertise, the accomplishments of its RORγT program and the immunology expertise of Janssen so that we will work together to discover new RORγT based treatments for autoimmune diseases. We hope that small molecule drugs that target RORγT will prove to be a safe, effective and affordable means to treat autoimmune disease, a marketplace within which there remains a need for differentiated therapies.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important